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Trypanosoma brucei rhodesiense (T.b.r.), the causative agent of the East African 
form of human African trypanosomiasis (HAT), is capable of crossing the blood 
brain barrier and invade the central nervous system (CNS). However, it is not clear 
whether bloodstream forms (BSF) of T.b.rhodesiense differ in biological 
characteristics from the cerebrospinal fluid (CSF) forms. The present study was 
carried out to compare the pathogenicity of CSF and BSF of T.b. rhodesiense 
parasites in Swiss white mice following intraperitoneal inoculation with 106 
trypanosomes. The parasites were tested for presence of the serum resistance 
associated (SRA) gene. Parasitaemia, body weight, packed cell volume (PCV) and 
survival of the mice was monitored daily until the experiment was terminated. Data 
was analyzed using general linear model. Both forms of parasite were positive for 
the SRA gene, and there was no significant difference in progression of 
parasitaemia, PCV values or survival of the mice. However, the weights of BSF 
infected mice initially dropped faster than those of CSF infected mice (P<0.001).  
Key words: Trypanosoma brucei rhodesiense, bloodstream and CSF forms, 
pathogenicity, and mice. 




Human African trypanosomosis (HAT) or 
sleeping sickness is caused by Trypanosoma 
brucei rhodesiense in east and southern Africa, 
and by T.b. gambiense in central and western 
Africa (1). The disease manifests in two 
sequential phases, an early stage when the 
parasites are demonstrated in haemolymphatic 
system and a second or late stage when parasites 
have invaded the central nervous system (CNS) 
(2). The mechanism through which the parasites 
cross the blood brain barrier (BBB) is not fully 
understood. It has been observed that in late 
stage disease, the BBB becomes compromised, 
allowing the trypanosome to pass into CNS 
more readily [3,4].  Previous studies reported 
that Trypanosoma b. brucei penetrates the CNS 
in areas such as the pituitary gland, where the  
 
BBB is lacking [5]. Other workers have 
proposed that trypanosomes enter into CNS by a 
process of transcytosis through the vascular 
endothelium [6]. 
            CSF is not a good medium for parasite 
growth and is thought to affect the phenotypic 
characteristics of the parasites [7, 8]. Pentreath 
has suggested that as the disease progresses, 
changes occur in the cerebrospinal fluid (CSF), 
making it more 'hostile' to the trypanosome [8]. 
An increase in the level of whiteblood cells, 
IgM, and cytokines as well as changes in 
physiological state of CSF could be responsible 
for changes in the parasite phenotypic 
characteristics. Indeed, it has been argued that 
rapidly dividing trypanosomes will eventually 
produce a number of genetic mutants [9]. 
Changes in the CSF physiological environment 
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may as a result select those parasites within the 
infra-population that can best survive in the 
altered environment [9]. Eventually, these 
parasites would have a different phenotype when 
compared to the bloodstream forms. 
Furthermore, when chronic T. brucei infections 
in mice are treated with suramin at 20mg/kg, 
relapsing trypanosomes from the brain exhibit a 
higher degree of human serum resistance than 
the original infection [10]. This could imply 
changes in the serum resistance associated 
(SRA) gene. It has also been observed that 
although T.b. rhodesiense parasites normally 
invade the CSF within 2 weeks after infection, 
parasites (following sub-curative therapy) can 
reside in the CSF for several months after 
relapses before invading the bloodstream. In the 
latter case, patients and animals rarely show any 
adverse clinical signs. However, the individuals 
later succumb to the meningoecephalitis caused 
by trypanosomes in the brain parenchyma 
(Ngotho J.M. personal communication). 
         It is not clear whether the trypanosomes in 
CNS are different in characteristics from the 
circulation forms. A World Health Organisation 
(WHO) scientific working group recommended 
that studies be carried out to determine whether 
there are differences between bloodstream and 
CSF trypanosomes [11].  This would improve 
the understanding of the pathogenesis of late 
stage sleeping sickness. The current study aimed 
at characterising two forms of trypanosomes 
isolated from a patient, based on their 
pathogenicity in the Swiss white mice.  
 
Materials and Methods 
 
Laboratory animals: Thirty-five Swiss white 
mice weighing 25-30g and obtained from 
Trypanosomiasis Research Centre (TRC) 
Animal Breeding Unit (Kenya) were used. Pre-
infection data on body weight and packed cell 
volume (PCV) was collected three times over a 
period of two weeks prior to inoculation with 
trypanosomes. The animals were de wormed by 
subcutaneous injection with ivermectin 
(Ivermectin® Anupco, England). They were 
maintained on a diet of commercial mice pellets 
(Mice pellets®, Unga Ltd, Nairobi, Kenya) and 
water ad libitum. 
Trypanosomes and preparation of inoculum: 
Two T.b. rhodesiense forms (KETRI 3537 
(BSF) and KETRI 3534 (CSF)) were isolated 
from an adult patient admitted at the former 
Kenya Trypanosomiasis Research Institute – 
Alupe, sleeping sickness referral hospital in 
1998. The parasites were initially passaged in 
Swiss white mice before being cryopreserved. 
During the experiment, the cryopreserved 
parasites were thawed and inoculated 
intraperitonially into two donor Swiss white 
mice for multiplication. At peak parasitaemia, 
the mice were euthanized by placing them in a 
chamber containing carbon dioxide (CO2) and 
bled from the heart. The blood was collected 
into a tube containing EDTA and trypanosomes 
quantified using the improved Neubauer 
chamber. An inoculum dose of 1 x 106 
trypanosomes was prepared using phosphate 
buffered saline containing glucose (PSG), pH 
8.0.  
 
Experimental design            
Mice: Adults male mice were infected by 
intraperitoneal injection with 1x106 
trypanosomes and grouped as follows: (i) 15 
infected with KETRI 3534, (ii) 15 infected with 
KETRI 3537, and (iii) 5 uninfected controls. The 
mice were monitored daily and the following 
parameters determined: prepatent period (PP), 
parasitaemia, PCV, weight and mortality. 
Packed cell volume (PCV) was determined as 
described by Cheesbrough [12] while 
parasitaemia was monitored using rapid 
matching technique [13]. All experimental 
procedures involving mice were reviewed and 
approved by the Animal Care and Use 
Committee (ACUC) of TRC. 
 
Polymerase chain reaction (PCR): DNA was 
prepared by the standard phenol extraction and 
alcohol precipitation method [14]. 
Approximately 10ng of trypanosome DNA was 
used as a template for each PCR reaction. The 
SRA primers used in this study as well as the 
PCR were as described by Gibson [12]. 
 
Statistical analysis: The SAS version 8 
statistical software was used to analyze the data, 
whereas the general linear model was used to 
compare the mean parasitaemia, PCV and 
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weights of the different groups. Survival 





Both the BSF and CSF trypanosomes tested 
positive for the SRA gene as evidenced by the 
presence of an amplification revealed on agarose 
gel electrophoresis (bp) (Figure 1) 
 
Parasitaemia   
Figure 2 shows the parasitaemia patterns in mice 
infected with BSF and CSF trypanosomes. Mice 
infected with BSF parasites had a prepatent 
period (PP) of 4 days (range = 3–5 days) and 
showed two waves of parasitaemia. The first 
peak of parasitaemia (1x109 trypanosomes/ml) 
occurred between 5 and 8 days post-infection 
(dpi). This was followed by a fall in mean 
parasitaemia to 2.5x107 trypanosomes/ml 
between 9 and 15 dpi, and a second peak (mean 
4 x 108 trypanosomes/ml) between 16 and 25 
dpi. The mice inoculated with CSF parasites had 
a PP of 4 days (range = 3 – 5 days) and three 
waves of parasitaemia. The first (mean 1 x 109 
trypanosomes/ml) occurred at 6 dpi, followed by 
a drop to a mean of 5x107 trypanosomes/ml 
between 7 and 12 dpi, then a slight increase to a 
mean of 2.5x108 trypanosomes/ml, which 
remained at this level for approximately 14 days. 
A further increase (mean 1 x 109 
trypanosomes/ml) occurred between 29 and 34 
dpi. Statistical analysis using general linear 
model showed no significant difference in these 
changes in parasitaemia between the BSF and 
CSF infected mice.  
          
          Figure 1. PCR amplification of the SRA gene from CSF and BSF of T.b. rhodesiense 
Key 
1) Negative control, 2) Test sample (CSF forms), 3) Negative control, 4) Test sample (Blood forms), 
NC-Negative control, PC- Positive control, M- markers  
 
Mice survival 
Figure 3 shows the survival rates of mice 
infected with BSF and CSF trypanosomes. The 
survival rate of BSF and CSF mice did not differ 
statistically between the 2 groups. However, the 
mortality of BSF infected mice was higher than 
that for the CSF infected mice. The mean 
survival period of BSF and CSF infected mice 
was 20.4 and 23 days, respectively.  
 
Packed cell volumes (PCV) 
The PCV values for both BSF and CSF infected 
mice were similar, but significantly lower than 
those of control non-infected mice (P 
=0.001,x2=17.09,df=1). PCV values of both BSF 
and CSF trypanosomes infected mice dropped 
from 49% to 35% within 7 dpi. The values for 
both groups dropped further to 21% by 21 dpi. 
Interestingly, PCV values of CSF infected mice 
increased slightly from 21% to 26% between 22 
and 34 dpi, but those for the BSF infected mice 
remained around 22% upto the end of 
experiment. There was no significant difference 
between the PCV changes in the mice infected 
with either the BSF or CSF forms of parasites. 
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     Fig 2. Parasitemia progression in mice infected with BSF and CSF forms of T.b. rhodesiense
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Mice changes in body weight 
The changes in body weight varied between 
controls, BSF and CSF infected mice (P=0.001, 
x2=58.24,df=1). Whereas the mean body weight 
of BSF infected mice fell from 22± 1.5g to 19.5 
± 3g by day 17 post infection, those of CSF 
infected mice fell from 21± 1.8g to 19± 2.4g 
within 13 dpi, and continued to fall gradually to 
18 ± 2g by 20 dpi. A steady but gradual increase 
in body weight was observed between 23 and 30 
dpi in CSF mice reaching 22 ±2.6 by 30 dpi. 
  
Discussion  
The present study was carried out to characterise 
BSF and CSF forms of T.b. rhodesiense isolated 
from a sleeping sickness patient, based on their 
pathogenicity in Swiss white mice. The PCR 
results showed the presence of the SRA gene in 
both parasite groups, demonstrating the 
conserved nature of the SRA gene, even as the 
trypanosomes cross the BBB into the CSF. 
Previous studies have shown that the SRA gene 
is ubiquitous and conserved in T.b. rhodesiense 
[14, 15] and as such, has potential for the 
development of a highly specific diagnostic tool. 
Although BSF and CSF parasites had similar 
prepatent periods (of 4 days) in mice, with the 
first peak of parasitaemia occurring 6 dpi, the 
pattern of parasitaemia after that differed 
between the 2 groups. Mice infected with BSF 
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parasites demonstrated fewer waves of 
parasitaemia than the mice infected with CSF 
forms. Expression of several waves of 
parasitaemia is an indicator of different variable 
antigen types (VATs) of trypanosomes to which 
immune response is elicited [16].   
           It can therefore be assumed that the 
antibodies raised against the CSF forms were 
capable of responding to the various VATs 
expressed, thus prolonging the life of the 
infected mice. Indeed, it was observed that the 
mortality rate of CSF infected mice was lower 
than in BSF infected mice. This concurs with 
results of earlier studies on relationships 
between parasitaemia and survival, that showed 
in cattle that the higher the parasitaemia, the 
greater the degree of pathogenicity [17]. It also 
turns out that the sex of the host also compounds 
the virulence of the trypanosomes, with females 
surviving longer than males [18, 19]. Since the 
mice used in the present study were inbred 
Swiss white of the same sex, the difference in 
survival observed between BSF and CSF mice 
can largely be attributed to differences in 
virulence between the 2 parasites. It has also 
been reported that immunosuppresion associated 
with trypanosomosis contributes significantly to 
survival of infected hosts [20]. It will be 
interesting to compare the relative 
immunosuppresion that occurs in mice infected 
with BSF and CSF forms of trypanosomes.  
         The onset of anaemia in mice infected with 
the two groups of parasite was marked by a drop 
in PCV, coinciding with the first peak of 
parasitaemia, and continued to decline as the 
infection progressed, in agreement with 
observations from previous studies [21, 22]. The 
gradual rise in PCV from at 21 dpi suggests a 
recovery in erythropoiesis.  Mice infected with 
the BSF and CSF forms had a fall in body 
weight drops between 13 and 15 dpi. This is not 
surprising, as similar observations have been 
reported in rats infected with T.b. brucei at 13-
dpi [23]. It has been suggested that the onset of 
weight loss could be associated with the 
initiation of second stage trypanosomosis in 
mice [24]. It is noted that body weight loss and 
anorexia are controlled by the hypothalamus, 
and as such the effect could be caused by entry 




Little is known about the differences in 
characteristics between BSF and CSF forms of 
T.b.rhodesiense isolated from the same patient. 
Results of the present study suggest 
conservation of the SRA gene in the CNS T.b 
rhodesiense trypanosomes. While no statistically 
significant differences were observed in 
parasitaemia, survival or PCV between mice 
infected with BSF and CSF forms, there was a 
statistically significant drop in weight in BSF 
infected mice, relative to the CSF mice. 
Considering that the CSF parasites are in an 
environment that may not be accessible to the 
vector and would only be accessible after 
relapses, it would be important to carry out a 
study to compare the transmissibility of the 
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